Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.
Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …
Bridging bench to bedside: Exosome‑based strategies for endometriosis diagnosis and treatment (Review).
Endometriosis is a complex, chronic inflammatory gynecological disorder with estrogen‑dependent characteristics that severely impairs the quality of life of women and potentially leads to infertility. However, its pathogenesis remains poorly …
High inhibition ratio and transformation index of 2 mg dienogest: further evidence for its use in endometriosis treatment.
Endometriosis is a common, chronic disease with a high burden for women, characterised by the implantation of endometrial cells outside the uterus. Many different treatments have been proposed for this …